



## Monitoren van VKA met de INR




## Overeenkomsten tussen de INR methoden

### Mediane INR (IQR):

- POCT-INR: 3.0 (2.7-3.6)
- Owren-INR: 2.5 (2.4-3.0)
- Quick-INR: 2.8 (2.6-3.3)



## Samenhang tussen de INR methoden



Overeenkomst tussen POCT-INR en lab-INR wordt kleiner naarmate INR hoger is

## Effect van antifosfolipiden antistoffen op INR verschillen

TABLE 2 Effect of antiphospholipid antibodies on INR agreement.

| INR method            | Assay      | nLA-ratio and aPL titers in patients with INR agreement, median (IQR) | nLA-ratio and aPL titers in patients without INR agreement, median (IQR) | P value |
|-----------------------|------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------|---------|
| POCT-INR vs Owren-INR | N = 21     |                                                                       | N = 12                                                                   |         |
|                       | LA-dRVVT   | 1.41 (1.16-1.61)                                                      | 1.81 (1.48-2.47)                                                         | .02     |
|                       | LA-APTT    | 1.98 (1.28-2.59)                                                      | 2.43 (1.78-3.17)                                                         | .15     |
|                       | aCL IgM    | 5.48 (4.41-6.81)                                                      | 5.93 (3.78-8.27)                                                         | .78     |
|                       | aCL IgG    | 11.31 (5.67-23.88)                                                    | 45.06 (8.81-405.52)                                                      | .06     |
|                       | aB2GPI IgM | 6.65 (6.30-8.13)                                                      | 7.00 (6.47-7.94)                                                         | .78     |
|                       | aB2GPI IgG | 7.97 (6.43-17.17)                                                     | 76.21 (20.80-305.08)                                                     | .002    |
|                       | aPS/PT IgM | 120.08 (32.72-208.88)                                                 | 235.07 (105.74-257.55)                                                   | .79     |
|                       | aPS/PT IgG | 38.98 (16.05-180.95)                                                  | 236.58 (87.89-258.99)                                                    | .04     |
| POCT-INR vs Quick-INR | N = 28     |                                                                       | N = 5                                                                    |         |
|                       | LA-dRVVT   | 1.48 (1.17-1.87)                                                      | 2.36 (1.72-2.57)                                                         | .03     |
|                       | LA-APTT    | 2.04 (1.49-2.74)                                                      | 2.43 (1.65-3.44)                                                         | .45     |
|                       | aCL IgM    | 5.42 (3.99-6.88)                                                      | 6.14 (5.09-9.38)                                                         | .12     |
|                       | aCL IgG    | 30.56 (5.94-39.44)                                                    | 403.80 (207.23-497.39)                                                   | .003    |
|                       | aB2GPI IgM | 6.42 (6.30-7.98)                                                      | 7.46 (7.07-8.93)                                                         | .13     |
|                       | aB2GPI IgG | 8.93 (6.66-35.04)                                                     | 229.44 (180.65-296.03)                                                   | <.001   |
|                       | aPS/PT IgM | 192.03 (32.83-295.22)                                                 | 176.76 (100.69-220.44)                                                   | .54     |
|                       | aPS/PT IgG | 113.79 (17.45-225.44)                                                 | 221.37 (99.38-259.84)                                                    | .14     |

## Correlatie tussen antistoftiters en INR verschillen

TABLE 3 Correlation of antiphospholipid antibody titers with INR differences.

| INR method            | Assay      | Spearman's $\rho$ | P value |
|-----------------------|------------|-------------------|---------|
| POCT-INR vs Owren-INR | LA-dRVVT   | 0.348             | .03     |
|                       | aB2GPI IgG | 0.536             | .001    |
|                       | aPS/PT IgG | 0.290             | .10     |
| POCT-INR vs Quick-INR | LA-dRVVT   | 0.191             | .29     |
|                       | aCL IgG    | 0.341             | .05     |
|                       | aB2GPI IgG | 0.525             | .002    |

Correlation between antibody titers and INR differences was assessed with Spearman's correlation coefficient ( $\rho$ ).

aCL, anticardiolipin antibody; aB2GPI, anti- $\beta$ 2-glycoprotein I antibody; aPS/PT, antiphosphatidylserine/prothrombin antibody; dRVVT, dilute Russell's Viper venom time; INR, international normalized ratio; LA, lupus anticoagulant; POCT, point-of-care testing.

## Take home message

Er is verschil in INR-waarden gemeten met de CoaguChek XS en laboratorium-INR bij een deel van de mensen met LAC

Laboratorium-INR monitoring (Owren methode) heeft de voorkeur boven POCT-INR monitoring in mensen met:

- Hoge anti- $\beta$ 2-glycoprotein I IgG antistoftiters
- POCT-INR > 3.0